Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2

Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2

US Patent 11807649 · Granted Nov 7, 2023

Estimated economic value: $7,128,000 ⓘ

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Compounds, compositions and methods2025
Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases2025
Compounds for the treatment of BRAF-associated diseases and disorders2025
Method for increasing number of proteins identified by mass spectrometry2025
5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases2025
5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases2025
5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases2025
Imaging methods using deuterated compounds2025
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kin2024
N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I r2024
Manufacturing method of an integrally formed inductor2024
Protective membrane for electrochemical cells2024